Kisspeptin
Kisspeptin-10 · KP-10 · Metastin · KISS1 peptide · KiSS1(112-121)
Last updated
At a glance
Overview
Kisspeptin is the only compound in the PCT toolkit that acts above the pituitary — it triggers the GnRH pulse generator itself, restoring the physiological rhythm that hCG, SERMs, and AIs can only work around. That upstream position is what has pulled it out of clinical endocrinology and into the hands of physique-focused users running post-cycle restarts, guys chasing libido recovery after finasteride or SSRIs, and anyone who wants to probe whether their HPG axis is actually responsive before committing to a long SERM protocol.
The catch is that kisspeptin is not a "take daily, forget about it" peptide. KISS1R desensitizes fast under continuous exposure — rodent data show LH response collapsing within 48 hours of non-stop dosing, and human pharmacology suggests the same ceiling. Pulsatile dosing is mandatory, and the difference between a protocol that works and one that flatlines your LH is entirely about timing, not dose size.
"Bolus intravenous administration of KP-10 (0.3 nmol/kg) significantly stimulated a rise in plasma LH concentration and increased LH pulse frequency in healthy men." — George JT et al., JCEM (2011)
This guide covers what kisspeptin actually does at the receptor level, the KP-10 vs KP-54 half-life question, evidence-based dose ranges for PCT restart and libido protocols, how to stack it with enclomiphene or tamoxifen without double-dipping on mechanism, the tachyphylaxis trap and how to pulse around it, and how it compares to hCG, gonadorelin, and straight SERM-based PCT.
How Kisspeptin works
Kisspeptin is the endogenous ligand of KISS1R (formerly GPR54), a G-protein coupled receptor expressed densely on hypothalamic GnRH neurons. Unlike hCG (which mimics LH at the testicle) or SERMs like clomiphene (which block estrogen feedback at the pituitary), kisspeptin acts upstream of everything — it is the trigger that tells the hypothalamus to fire GnRH pulses, restarting the entire HPG cascade from the top.
KISS1R Activation and GnRH Release#
Kisspeptin binds KISS1R on GnRH neurons in the arcuate and preoptic nuclei, activating the Gq/PLC pathway → IP₃/DAG → intracellular Ca²⁺ mobilization. This depolarizes the neuron and drives pulsatile GnRH release into the hypophyseal portal system. GnRH then hits the anterior pituitary, which secretes LH and FSH; LH drives Leydig-cell testosterone production, FSH supports Sertoli-cell spermatogenesis.
The key physiological point: kisspeptin restores native pulsatility, not tonic stimulation. This is why it can restart a suppressed axis in a way hCG structurally cannot — hCG bypasses the hypothalamus and pituitary entirely, keeping them asleep.
"Acute intravenous administration of KP-54 increased plasma LH, FSH, and testosterone concentrations, indicating a robust activation of the reproductive axis in healthy adult men." — Dhillo WS et al., Journal of Clinical Endocrinology & Metabolism, 2005
LH Pulse Generation via KNDy Neurons#
The arcuate kisspeptin neurons co-express neurokinin B and dynorphin (the so-called KNDy neurons) and function as the actual GnRH pulse generator — the biological clock that paces the reproductive system. Exogenous kisspeptin essentially overrides a sluggish or suppressed endogenous pulse generator and imposes a fresh rhythm.
This translates practically: a single SC bolus of KP-10 raises LH pulse frequency, not just amplitude. For a post-cycle user whose hypothalamus has gone quiet under months of androgen feedback, this is exactly the input needed to re-establish the native rhythm.
"Bolus intravenous administration of KP-10 (0.3 nmol/kg) significantly stimulated a rise in plasma LH concentration and increased LH pulse frequency in healthy men." — George JT et al., Journal of Clinical Endocrinology & Metabolism, 2011
Pulsatile vs Continuous — The Tachyphylaxis Trap#
KISS1R desensitizes rapidly under continuous exposure, in the same way GnRH agonists like leuprolide flip from stimulation to suppression with chronic dosing. This is the single most important dosing fact for anyone running kisspeptin:
| Dosing pattern | LH response | Outcome |
|---|---|---|
| Single bolus or intermittent pulses | Robust rise, preserved over weeks | Functional restart |
| Continuous infusion / high daily dose | Flattens within 24–48 h | Desensitization; testicular atrophy in rodents over ~13 days |
"Continuous administration of kisspeptin-54 resulted in desensitization of the LH response by 48 hours and caused marked testicular degeneration after 13 days." — Thompson EL et al., American Journal of Physiology Endocrinology and Metabolism, 2006
This is why community protocols converge on pulsed dosing — 100 mcg 1–2× daily, 5 days on / 2 days off, or EOD for 4–6 weeks. Dose it like a trigger, not a drip.
Central Effects on Libido and Sexual Behavior#
Kisspeptin receptors are not confined to the hypothalamus. KISS1R is expressed in limbic structures — amygdala, hippocampus, anterior cingulate — where kisspeptin modulates sexual and emotional processing independently of downstream testosterone. fMRI work in healthy men shows kisspeptin enhances brain activation to sexual and couple-bonding cues, and blunts negative mood responses to aversive stimuli.
This is mechanistically why users report libido and morning-erection improvements faster than any testosterone rise could explain, and why post-finasteride and PSSD users run low microdoses for symptom relief rather than for HPG restart per se. The effect is partly central, not just endocrine.
"Kisspeptin administration enhanced limbic brain activity in response to sexual and couple-bonding stimuli, suggesting a central role in modulating sexual behavior and mood." — Comninos AN et al., Journal of Clinical Investigation, 2017
Preserved Response Across Age#
One of kisspeptin's more useful features for the TRT-recovery and older-lifter demographic: the hypothalamic response doesn't meaningfully attenuate with age. Older men with age-related testosterone decline still mount full LH/FSH/T responses to kisspeptin infusion, which means the axis in most suppressed or aging users is functionally intact but quiet — not broken. It needs a kick, not a replacement.
"Kisspeptin-54 infusion produced comparable increases in LH, FSH, and testosterone in both younger and older men, with no significant age-related attenuation of response." — Abbara A et al., Neuroendocrinology, 2018
Practically, this makes kisspeptin a useful diagnostic probe as well as a therapeutic — a single 100 mcg SC dose with LH drawn at 60 min tells you whether the hypothalamic-pituitary machinery is responsive before you commit to a full SERM-based restart. A robust LH rise means the axis will come back; a flat response points you toward a pituitary issue that kisspeptin alone won't fix.
Protocol
| Level | Dose | Frequency | Notes |
|---|---|---|---|
| Low | 25–50 mcg | Twice daily | Documented entry-level range |
| Mid | 100–200 mcg | Twice daily | Most commonly studied range |
| High | 200–600 mcg | Twice daily | Pulsatile dosing is mandatory — KISS1R desensitizes rapidly under continuous exposure. Typical pattern: 100 mcg SC 1–2× daily, 5 days on / 2 days off. Do NOT dose continuously at high levels; this flattens the LH response within 24–48h (Thompson 2006). |
Cycle length & outcomes
Documented cycle
2–6 weeks
Plateau after
6 wks
Cycle Length & Dosing by Goal#
Kisspeptin is unusual among PCT tools: the dosing constraint isn't tolerance or shutdown, it's receptor desensitization. KISS1R flattens out under continuous exposure within 24–48 hours, so the cycle structure is built around pulsatile dosing — never flat, never continuous, never "more is better."
| Goal | Cycle Length | Dose | Frequency |
|---|---|---|---|
| Diagnostic probe (LH response test) | Single dose | 100 mcg SC | One-off bolus, LH drawn at 60 min |
| Post-finasteride / PSSD libido rescue | 4–6 weeks | 1–5 mcg (micro) or 25–50 mcg | 2–3× daily, pulsed |
| Standalone HPG restart (mild suppression) | 3–4 weeks | 100 mcg SC | 1–2× daily, 5 on / 2 off |
| Full PCT with SERM (post-AAS cycle) | 4–6 weeks | 100–200 mcg SC | 2× daily, 5 on / 2 off |
| Fertility-focused restart (with hMG/hCG) | 4–8 weeks | 100 mcg SC | Daily pulsed, 5 on / 2 off |
Onset & What to Expect#
Kisspeptin acts fast. LH rises within 30–60 minutes of a subcutaneous shot, testosterone peaks 60–90 minutes post-injection, and the downstream effect lasts 3–6 hours despite KP-10's 3–5 minute plasma half-life. That decoupling is the whole point — you're triggering a pulse, not maintaining a serum level.
"Bolus intravenous administration of KP-10 (0.3 nmol/kg) significantly stimulated a rise in plasma LH concentration and increased LH pulse frequency in healthy men." — George JT et al., JCEM 2011
Subjectively, most users notice libido and morning erections within the first week. Testosterone recovery on bloodwork lags behind — expect meaningful shifts by week 2–3, and use the week 4–6 draw as your real verdict.
The Tachyphylaxis Trap#
This is the one thing you cannot get wrong. Rat data showed that continuous KP-54 infusion flattened the LH response within 48 hours and produced testicular degeneration at 13 days:
"Continuous administration of kisspeptin-54 resulted in desensitization of the LH response by 48 hours and caused marked testicular degeneration after 13 days." — Thompson EL et al., AJP Endocrinol 2006
Translation: dosing 200 mcg every 4 hours around the clock doesn't give you a bigger restart — it gives you less restart than 100 mcg twice daily with a weekend off. Pulsatile spacing is mandatory. The community standard of 5 days on / 2 days off exists specifically to keep KISS1R responsive across a multi-week block.
Loading & Tapering#
No loading phase. No taper. Kisspeptin works from dose one, and you simply stop when the cycle ends — there's no withdrawal, no rebound suppression, no HPG crash. If the restart took, the axis is now self-sustaining on its own GnRH pulse generator; if it didn't, you escalate to SERMs or hCG rather than extending kisspeptin indefinitely.
Bloodwork Cadence#
Restart cycles live or die on labs. Minimum panel: LH, FSH, total T, free T, E2 (sensitive), SHBG, prolactin.
- Baseline — before first injection, ideally 2–3 weeks after last long-ester AAS has cleared
- Week 2 — confirm the axis is responding (LH should be trending up; T following)
- Week 4–6 — end-of-cycle verdict
- 4–6 weeks post-cessation — the critical draw. This tells you whether the axis is self-sustaining or whether you need a follow-up SERM block
Age doesn't blunt the response meaningfully — the hypothalamic machinery stays intact:
"Kisspeptin-54 infusion produced comparable increases in LH, FSH, and testosterone in both younger and older men, with no significant age-related attenuation of response." — Abbara A et al., Neuroendocrinology 2018
Stacking Context#
For post-AAS restart, pair with a low-dose SERM — enclomiphene 12.5 mg EOD or tamoxifen 10 mg/day — for the full 4–6 weeks. The SERM handles pituitary sensitivity by blocking estrogen negative feedback; kisspeptin handles hypothalamic drive upstream. They work on different levels of the axis and genuinely stack rather than overlap.
For libido / PSSD protocols, kisspeptin pairs cleanly with daily low-dose tadalafil (2.5–5 mg) — the central effect on sexual-brain circuitry plus peripheral vascular support is a well-matched combo, and fMRI work confirms kisspeptin's limbic action is real and distinct from its endocrine effects (Comninos 2017, JCI).
What you don't do: run it on-cycle alongside active AAS. Exogenous androgens are already suppressing you via long-loop feedback; kisspeptin on top is pharmacologically pointless and wastes the desensitization budget you'll want intact for the actual restart.
Risks & mistakes
Common (most users)#
- Injection-site reactions — mild erythema, transient itch, occasional small wheal. Rotate sites (abdomen, flank, thigh), use insulin syringes (29–31G), and let the bac-water-reconstituted peptide come to room temperature before injecting.
- Flushing and warmth in the minutes after a bolus — more pronounced with IV dosing than SC. Not dangerous; subsides within 15–30 minutes. If it bothers you, split the dose or drop from 200 mcg to 100 mcg per pulse.
- Mild headache — typically dose-dependent. Hydrate, pair with food, and consider moving the injection away from training or high-sympathetic periods.
- Transient nausea at higher bolus doses (200+ mcg SC). Split into two smaller pulses spaced 6–8 hours apart instead of a single large bolus.
- Spontaneous erections / libido surge in the first 1–3 hours post-dose — this is expected pharmacology, not a side effect. Time your injections around this if it's inconvenient (or don't, if it isn't).
- Mood activation / mild anxiety or stimulation — consistent with central limbic effects documented on fMRI. Usually settles after the first few doses as you recalibrate.
"Kisspeptin administration enhanced limbic brain activity in response to sexual and couple-bonding stimuli, suggesting a central role in modulating sexual behavior and mood." — Comninos AN et al., Journal of Clinical Investigation (2017)
Uncommon (dose-dependent or individual)#
- Blunted LH response over time — the classic tachyphylaxis issue. If your bloodwork shows LH stalling or falling despite continued dosing, you are dosing too frequently or too high. Drop to every-other-day or implement a strict 5-on / 2-off pattern.
- Estradiol overshoot during restart — as endogenous T climbs, E2 climbs with it. Pull sensitive E2 at week 2. If it's trending high and you're symptomatic, a low-dose AI (anastrozole 0.25 mg twice weekly) or tamoxifen 10 mg/day handles it cleanly.
- Prolactin elevation — uncommon but reported anecdotally. Check prolactin at week 2–4 if you're getting nipple tenderness, mood flatness, or ED despite rising T.
- Anxiety / insomnia in sensitive users, particularly with evening dosing or stacked with other stimulating peptides. Shift dosing to morning and early afternoon.
- No measurable LH rise on a probe dose — points to pituitary dysfunction, not a kisspeptin problem. Pull full pituitary labs (LH, FSH, prolactin, IGF-1, cortisol, TSH) before continuing.
"Continuous administration of kisspeptin-54 resulted in desensitization of the LH response by 48 hours and caused marked testicular degeneration after 13 days." — Thompson EL et al., American Journal of Physiology Endocrinology and Metabolism (2006)
Rare but serious#
- Testicular degeneration from continuous high-dose exposure — demonstrated in rats under continuous 50 nmol/day SC infusion (Thompson 2006). Not documented in humans on pulsatile protocols, but it is the reason the pulsatile rule exists. Warning signs: testicular ache, shrinkage, or a paradoxical drop in T on labs. Stop immediately and reassess.
- Unintended ovulation in women — kisspeptin is used clinically as an IVF trigger. In a woman of reproductive age not seeking pregnancy, this is a pregnancy-risk event, not a minor side effect.
- Driving growth of an occult hormone-sensitive tumor — kisspeptin raises endogenous T and E2. In anyone with undetected prostate or breast pathology, this is the mechanism to worry about. Get a PSA and a physical exam before starting if you're over 40 or have family history.
- Severe hypersensitivity / injection-site reaction — very rare for a small peptide, but possible with any parenteral. Stop if you see spreading rash, swelling beyond the injection site, or respiratory symptoms.
Hard contraindications#
- Hormone-sensitive malignancy — active or history of prostate cancer, breast cancer, or other androgen/estrogen-driven tumor. Do not use kisspeptin. The entire point of the compound is to raise endogenous sex steroids.
- Active AAS cycle — pointless and counterproductive. Exogenous androgen feedback is already suppressing you at the hypothalamus; kisspeptin can't punch through that, and chronic dosing while suppressed just burns receptor responsiveness for the restart.
- Women of reproductive age not seeking pregnancy, without reliable non-hormonal contraception — kisspeptin triggers ovulation. It is not contraceptive-compatible.
- Untreated hyperprolactinemia or known pituitary disease — the axis downstream of kisspeptin is broken; fix the pituitary first (cabergoline, imaging, workup) before attempting a kisspeptin-driven restart.
- Continuous (non-pulsatile) dosing — not a patient contraindication but a protocol one. Do not dose continuously at therapeutic levels. The LH response flattens within 24–48 hours and you waste the cycle.
Gender and PCT considerations#
Men (the primary audience here): kisspeptin is non-virilizing, non-hepatotoxic, non-suppressive (the opposite — it drives the axis), and does not require its own PCT. It is the PCT, or part of it.
Women: the compound is not inherently dangerous to the female body — it's used in IVF clinics — but its downstream effect is ovulation induction, which makes it inappropriate for the physique / looksmaxxing use case in any woman who could become pregnant. There is no meaningful physique-enhancing reason for a woman to run kisspeptin.
PCT role: kisspeptin restores upstream hypothalamic drive that neither SERMs (which act at the pituitary/hypothalamus via estrogen receptor blockade) nor hCG (which acts directly on the testis) replicate. After heavier cycles — long esters, 19-nors, multi-compound stacks — pair it with a SERM (enclomiphene 12.5 mg EOD or tamoxifen 10 mg/day) for 4–6 weeks rather than running it alone. After light cycles or for post-finasteride libido work, it can stand alone. Bloodwork at baseline, week 2, end of protocol, and 4–6 weeks post-cessation confirms the axis is self-sustaining.
"Kisspeptin-54 infusion produced comparable increases in LH, FSH, and testosterone in both younger and older men, with no significant age-related attenuation of response." — Abbara A et al., Neuroendocrinology (2018)
Run pulsatile, stack intelligently, draw labs, and kisspeptin is one of the best-tolerated restart tools available.
Stack & combine
Multipliers applied when these compounds run together. Values > 1 indicate a bonus on that axis. Tap a partner to expand the mechanism.
| Partner | Type | Lean | Fat loss | Recovery |
|---|---|---|---|---|
| synergistic | ×1.15 | ×1.00 | ×1.25 |
Featured in stacks1 curated protocol include Kisspeptin
FAQ — Kisspeptin
Where to buy
Swiss Chems
Affiliate link — we may earn a commission at no cost to you.
- Buy Kisspeptin-10 10mg (1 vial) - SwissChems - Buy Best Quality Peptides, SARMS OnlineBuy Kisspeptin
Real Peptides
Affiliate link — we may earn a commission at no cost to you.
- Kisspeptin-10Buy Kisspeptin
Research & citations
5 studies cited on this page.
Conclusion
Kisspeptin is the most upstream and physiologically elegant HPG-axis restart tool available — but you have to get the dosing and timing right for it to do its job.
Key takeaways:
- Standard PCT dose: 100 µg subcutaneous, 1–2× daily, pulsed (5 days on / 2 days off)
- Always use pulsatile/intermittent dosing — continuous exposure kills the LH response fast (Thompson 2006)
- Stacks well with low-dose SERM (tamoxifen 10 mg or enclomiphene 12.5 mg EOD) for robust restart
- Typical cycle: 2–6 weeks, starting only after exogenous androgens have cleared
- Minimal side effects when run properly; watch for site irritation and transient flushing at higher doses
- No direct gains in muscle or fat loss — this is a pure HPG restart and libido tool, not a growth driver
If you're looking for a cleaner, physiologically natural axis restart — and want a PCT solution that acts upstream of hCG or SERMs — kisspeptin is a high-leverage, low-risk addition to your post-cycle stack.